Novartis: security label reinforced for Beovu in the EU

(CercleFinance.com) - Novartis has announced that the CHMP has approved an update to the safety label of its Beovu (brolucizumab) to include information regarding retinal vasculitis and retinal vascular occlusion.


This update is applicable in the 27 EU member states, as well as the UK, Norway, Iceland and Lichtenstein. Beovu is now approved in wet LDMA in over 40 countries, including the US, the EU and Japan.


Copyright (c) 2020 CercleFinance.com. All rights reserved.